| Literature DB >> 31814744 |
Ziyan Kong1, Rui Cai1, Chen Cheng1, Chuanling Zhang2, Haiquan Kang3, Ping Ma3, Bing Gu1,3.
Abstract
PURPOSE: Carbapenem-resistant Klebsiella pneumoniae (CRKP) have emerged worldwide and also being a major threat to children and neonate. In this study, we describe a nosocomial outbreak of NDM-5-producing Klebsiella pneumoniae in neonatal unit of a teaching hospital in China from September 2015 to September 2016. PATIENTS AND METHODS: We collected 12 carbapenem-resistant K. pneumoniae outbreak strains from 12 newborns and characterized these isolates for their antimicrobial susceptibility, clone relationships, and multi-locus sequence types using vitek-2 compact system, pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST). Resistant genes were detected by using PCR and sequencing. Plasmid conjugation experiment was carried out to determine the transferability of carbapenem resistance. PCR-based replicon typing (PBRT), S1 nuclease-PFGE, and southern blotting were conducted for plasmid profiling.Entities:
Keywords: IncX3; Klebsiella pneumoniae; ST337; blaNDM-5; carbapenemases; neonate
Year: 2019 PMID: 31814744 PMCID: PMC6863125 DOI: 10.2147/IDR.S218945
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Primers Used For Amplification Of The Resistance Genes Of K. pneumoniae In This Study
| Resistance Gene | Primer | Size Of PCR Product (bp) | References |
|---|---|---|---|
| F: ATG TCA CTG TAT CGC CGT C | 882 | ||
| R: TTA CTG CCC GTT GAC GCC | |||
| F: GAAGCTGAGCACCGCATTAG | 982 | ||
| R: GGGCCGTATGAGTGATTGC | |||
| F: GCMCTTCTCGCGGAGATTGA | 257 | ||
| R: TGCGCAGCACCRGGATAGA | |||
| F: TTGGTGGCATCGATTATCGG | 743 | ||
| R: GAGCACTTCTTTTGTGATGGC | |||
| F: CTACCGCAGCAGAGTCTTTG | 587 | ||
| R: AACCAGTTTTGCCTTACCAT | |||
| F: CAGCGCTTTTGCCGTCTAAGC | 945 | ||
| F: GGCCCATGGTTAAAAAATCACTGC | |||
| F: CTC AGA GCA TTC GCC GCT CA | 848 | ||
| R: CCG CCG CAG CCA GAA TAT CC | |||
| F: ACTTCAGCCACACGGATTCA | 1024 | ||
| R: CGA GTA CGT CAC GAC GAC TT | |||
| F: GTTACAGCCCTTCGGCGATGATTC | 881 | ||
| R: GCGCATGGTGACAAAGAGAGTGCAA | |||
| F: CGCCGGGTTATTCTTATTTGTCGC | 1017 | ||
| R: TCT TTCCGATGCCGCCGCCAGTCA | |||
| F: ATA AAATTCTTGAAGACGAAA | 1080 | ||
| R: GACAGTTACCAATGCTTAATCA | |||
| F: TGGCCAGAACTGACAGGCAA | 462 | ||
| R: TTTCTCCTGAACGTGGCTGG | |||
| F: GCTGCTCAAGGAGCACAGGAT | 520 | ||
| R: CACATTGACATAGGTGTGGTGC | |||
| F: AACTTTCACAGGTGTGCTGGGT | 405 | ||
| R: CCGTACGCATACTGGCTTTGC | |||
| F: TCGGTAAAGCCGATGTTGCGG | 302 | ||
| R: CTTCCACTGCGGCTGCCAGTT | |||
| F: AACATGGGGTATCAGGGAGATG | 190 | ||
| R: CAAAGCGCGTAACCGGATTGG |
Clinical Features Of The Neonates In This Study
| Case | Sex | Pregnancy Duration (wk) | Birth wt (g) | Dates Of Hospital Stay | Date Isolate Identified | Specimen | Type(s) Of Infections | Antimicrobial Therapy | Clinical Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 35 | 3000 | 1 Sep–17 Sep 2015 | 10 Sep 2015 | Sputum | NP, NRDS | MOX | Improvement |
| 2 | M | 36 | 1600 | 2 Sep–28 Sep 2015 | 11 Sep 2015 | Sputum | NRDS | MOX+CAZ | Improvement |
| 3 | M | 40 | 3400 | 18 Dec 2015–13 Jan 2016 | 23 Dec 2015 | Sputum | NP | CAZ | Improvement |
| 4 | F | 42 | 3100 | 22 Dec 2015–6 Jan 2016 | 24 Dec 2015 | Sputum | NP | CTX | Improvement |
| 5 | M | 39 | 3500 | 30 Dec 2015–8 Jan 2016 | 31 Dec 2015 | Sputum | NP | MOX+AMS | Improvement |
| 6 | F | 40 | 3300 | 29 Dec 2015–7 Jan 2016 | 1 Jan 2016 | Urine | NP | MOX+AMS | Improvement |
| 7 | F | 40 | 3300 | 18 Jan −7 Feb 2016 | 26 Jan 2016 | Sputum | NP | MOX+AMS | Improvement |
| 8 | M | 39 | 3450 | 7 Feb −14 Mar 2016 | 8 Mar 2016 | Blood | NP, NS | MOX +AMC | Improvement |
| 9 | F | 38 | 3300 | 20 Jul–2 Aug 2016 | 29 Jul 2016 | Sputum | NP, NRDS | CAZ | Improvement |
| 10 | M | 34 | 1500 | 22 Aug–2 Oct 2016 | 27 Aug 2016 | Sputum | NP, NRDS | CAZ+TZP | Improvement |
| 11 | M | 35 | 2590 | 3 Sep–14 Sep 2016 | 4 Sep 2016 | Sputum | NP | CAZ | Improvement |
| 12 | F | 40 | 3000 | 10 Sep–20 Sep 2016 | 18 Sep 2016 | Blood | NP, NS | MOX +AMC | Improvement |
Abbreviations: M, male; F, female; NP, neonatal pneumonia; NRDS, neonatal respiratory distress syndrome; NS, neonatal sepsis; MOX, moxalactam; CAZ, ceftazidime; CTX, cefotaxime; AMS, amoxicillin-sulbactam; AMC, amoxicillin-clavulanate; TZP, piperacillin-tazobactam.
Antibiotic Resistance Characteristics Of The 12 NDM-5-Positive K. pneumoniae Isolates And Their Corresponding Transconjugants
| Isolate No. | Antimicrobial Resistance Genes | Minimum Inhibitory Concentration (μg/mL) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEM | IPM | ATM | CTX | CAZ | FEP | AM | CPFX | LE | AMC | TZP | SCF | SMZ-TMP | TG | PB | ||
| KP1 | 8 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP2 | ≥16 | ≥16 | 16 | ≥64 | ≥64 | ≥32 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| KP3 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 1 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP4 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP5 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP6 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP7 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP8 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 1 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP9 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP10 | 8 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | ≤0.25 | ≤0.25 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP11 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| KP12 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 | |
| EC600-1 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-2 | 8 | 8 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-3 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-4 | ≥16 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-5 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-6 | ≥16 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-7 | 4 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-8 | ≥16 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-9 | 4 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-10 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-11 | 4 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600-12 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 | |
| EC600 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤2 | ≤0.25 | ≤0.12 | 2 | 2 | 2 | ≤20 | ≤0.5 | ≤0.5 | |
Abbreviations: MEM, meropenem; IPM, imipenem; ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; AM, amikacin; CPFX, ciprofloxacin; LE, levofloxacin; AMC, amoxicillin-clavulanate; TZP, piperacillin/tazobactam; SCF, sulbactam/cefoperazone; SMZ-TMP, compound Sulfamethoxazole; TG, tigecycline; PB, polymixin B.
Figure 1Dendrogram of PFGE profiles of 12 blaNDM-5-positive Klebsiella pneumoniae isolates.
Figure 2blaNDM-5-carrying plasmid analysis (Top: S1-nuclease PFGE patterns; Bottom: Southern hybridization of the blaNDM-5 probe, which was hybridized to the roughly 45 kb plasmid to confirm the presence of the resistant plasmid in the 12 ST337 carbapenem-resistant K. pneumoniae strains). Lane M: marker (Salmonella H9812); KP1 to KP12: Klebsiella pneumoniae outbreak strains.